GlassScriptPhysician profile
Timothy Edward Ryan
NPI 1760914717
$85,200.27
in general payments reported to CMS, 2019-2025
41 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $262 · 2023: $1,076 · 2024: $25K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Travel and Lodging: $11K · Food and Beverage: $5,846 · Consulting Fee: $467 · Education: $82.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,929.50 |
| Travel and Lodging | $11,482.18 |
| Food and Beverage | $5,845.89 |
| Consulting Fee | $466.67 |
| Education | $82.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27,937.02 | 2023-2025 | Hyqvia |
| Neurelis, INC. | $27,329.83 | 2023-2025 | Valtoco |
| Janssen Biotech, INC. | $20,949.25 | 2025 | |
| Ucb, INC. | $5,420.78 | 2022-2025 | Nayzilam, Briviact, Fintepla |
| Livanova USA, INC. | $860.67 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Vertex Pharmaceuticals Incorporated | $466.67 | 2024 | |
| Argenx US, INC. | $425.58 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $322.65 | 2021-2025 | |
| Amgen INC. | $153.81 | 2022-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $132.21 | 2023-2025 | |
| Lilly USA, LLC | $103.56 | 2023-2024 | Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $103.05 | 2022-2025 | Ultomiris |
| Genzyme Corporation | $89.18 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $85.82 | 2022-2025 | Nuplazid |
| Averitas Pharma INC. | $61.47 | 2024-2025 | Qutenza |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.